Mys­tery solved? Nek­tar chief says 'soft­en­ing' in pa­tient re­spons­es to be­m­peg was a CMC is­sue — spurring a rout

Nek­tar CEO Howard Robin says his top team has been puz­zling out the rea­son why the re­sponse rates for their close­ly-watched drug NK­TR-214 (be­m­pe­galdesleukin) “soft­ened up” over time — with dis­as­trous con­se­quences. But the ex­pla­na­tion didn’t sat­is­fy any­one.

In fact, their stock $NK­TR plunged close to 33% af­ter the ex­pla­na­tion, shred­ding more than $1.5 bil­lion in mar­ket cap. And that’s not what Robin was look­ing for.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER